From Cheese to Pharma: A Designer Probiotic for IBD
- 31 July 2006
- journal article
- editorial
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (7) , 836-837
- https://doi.org/10.1016/j.cgh.2006.05.034
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A Phase I Trial With Transgenic Bacteria Expressing Interleukin-10 in Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2006
- Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiotaImmunological Reviews, 2005
- Diversity of the Human Intestinal Microbial FloraScience, 2005
- Animal models of intestinal inflammation: ineffective communication between coalition membersSpringer Seminars in Immunopathology, 2005
- Host-Bacterial Mutualism in the Human IntestineScience, 2005
- Modulation of human dendritic cell phenotype and function by probiotic bacteriaGut, 2004
- Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γ and RelANature Immunology, 2003
- Probiotic Bacterium Prevents Cytokine-induced Apoptosis in Intestinal Epithelial CellsJournal of Biological Chemistry, 2002
- Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's diseaseGastroenterology, 2000
- Prokaryotic Regulation of Epithelial Responses by Inhibition of IκB-α UbiquitinationScience, 2000